Literature DB >> 15809207

Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.

Michel Jourdan1, Karène Mahtouk, Jean-Luc Veyrune, Guilhem Couderc, Geneviève Fiol, Nicole Redal, Christophe Duperray, John De Vos, Bernard Klein.   

Abstract

Primary myeloma cells rapidly apoptose as soon as they are removed from their bone-marrow environment. A likely explanation is that the tumor environment produces survival factors that may counteract a spontaneous activation of pro-apoptotic program. Additional factors may trigger cell cycling in surviving myeloma cells. Interleukin-6 (IL-6) is a well recognized myeloma cell growth factor produced mainly by the tumor environment. However, myeloma cells themselves may produce low levels of autocrine IL-6. The respective roles of paracrine versus autocrine IL-6 are a matter of debate. We investigated these roles using the XG-6 myeloma cell line whose growth is dependent on addition of exogenous IL-6, despite its weak IL-6 mRNA and protein expression. The apoptosis induced by exogenous IL-6 deprivation was blocked by transferring the Mcl-1 gene coding for an anti-apoptotic protein in XG-6 cells. An XG-6Mcl-1 cell line which can survive and grow without adding IL-6 was obtained. We show that anti-IL-6 or anti-gp130 antibodies abrogated cell cycling whereas they did not affect cell survival. These data indicate that the weak autocrine IL-6 produced by myeloma cells is sufficient to trigger cell cycling whereas their survival requires large exogenous IL-6 concentrations. This important role of autocrine IL-6 has to be considered when evaluating the mechanism of action of myeloma cell growth factors. These factors may actually block an activated pro-apoptotic program, making possible a weak production of autocrine IL-6 to promote cell cycling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809207

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  11 in total

1.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer.

Authors:  Marco Archetti; Daniela A Ferraro; Gerhard Christofori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

2.  Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Authors:  Matthieu Schoenhals; Alboukadel Kassambara; Jean-Luc Veyrune; Jerome Moreaux; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

3.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

4.  An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

Authors:  Michel Jourdan; Anouk Caraux; John De Vos; Geneviève Fiol; Marion Larroque; Chantal Cognot; Caroline Bret; Christophe Duperray; Dirk Hose; Bernard Klein
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

5.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

6.  Stable heterogeneity for the production of diffusible factors in cell populations.

Authors:  Marco Archetti
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.

Authors:  Javad Salimi Sartakhti; Mohammad Hossein Manshaei; Soroosh Bateni; Marco Archetti
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

8.  Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Authors:  Alboukadel Kassambara; Matthieu Schoenhals; Jérôme Moreaux; Jean-Luc Veyrune; Thierry Rème; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  Enhancement of hybridoma formation, clonability and cell proliferation in a nanoparticle-doped aqueous environment.

Authors:  Natalie Gavrilov-Yusim; Ekaterina Hahiashvili; Marina Tashker; Victoria Yavelsky; Ohad Karnieli; Leslie Lobel
Journal:  BMC Biotechnol       Date:  2008-01-14       Impact factor: 2.563

10.  Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.

Authors:  Hsiao-Yun Chen; Liang-Ting Lin; Mong-Lien Wang; Shu-Hsien Lee; Ming-Long Tsai; Chi-Chang Tsai; Wei-Hsiu Liu; Tzu-Chien Chen; Yi-Ping Yang; Yi-Yen Lee; Yuh-Lih Chang; Pin-I Huang; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou; Ming-Teh Chen
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.